Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab

被引：0
|
作者：
Reck, Martin
Granados, Ana Laura Ortega
de Marinis, Filippo
Meyers, Oren
Boklage, Susan
Shen, Qin
Cho, Lillian
机构：
[1] Lungen Clin, Grosshansdorf, Germany
[2] Hosp Univ Jaen, Serv Oncol Med, Jaen, Spain
[3] European Inst Oncol, Milan, Italy
[4] GSK, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9099
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
    Wang, Hao
    Liao, Li
    Xu, Yuan
    Long, Yunchun
    Wang, Ye
    Zhou, Yujie
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Maintenance chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC)
    Belalcazar, A.
    Santos, E. S.
    Gomez, J. E.
    Lopez, E.
    Raez, L. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3
    Makharadze, Tamta
    Quek, Ruben G. W.
    Melkadze, Tamar
    Gogishvili, Miranda
    Ivanescu, Cristina
    Giorgadze, Davit
    Dvorkin, Mikhail
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    Gessner, Christian
    Moreno-Jaime, Brizio
    Passalacqua, Rodolfo
    Konidaris, Gerasimos
    Rietschel, Petra
    Gullo, Giuseppe
    CANCER, 2023, 129 (14) : 2256 - 2265
  • [44] Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China
    Liu, Huiqin
    Wang, Ying
    He, Qi
    HEALTH ECONOMICS REVIEW, 2022, 12 (01)
  • [45] Clinical Study of Pemetrexed as the First-line Treatment in Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer
    Pu Xiaolin
    Wang Jun
    Li Wei
    Lu Binbin
    Wang Zhaoxia
    Yang Min
    Fan Weifei
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2013, 1 (04): : 205 - 209
  • [46] MO19390 (SAiL): hypertension in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line bevacizumab plus chemotherapy
    Thatcher, Nicholas
    Tsai, Chun-Ming
    Laskin, Janessa
    Crino, Lucio
    Pavlakis, Nick
    Garrido, Pilar
    Dansin, Eric
    Bearz, Alessandra
    Hirsh, Veral
    Griesinger, Frank
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S358 - S359
  • [47] A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
    Tamiya, Motohiro
    Tamiya, Akihiro
    Kaneda, Hiroyasu
    Nakagawa, Kazuhiko
    Yoh, Kiyotaka
    Goto, Koichi
    Okamoto, Hiroaki
    Shimokawa, Tsuneo
    Abe, Tetsuya
    Tanaka, Hiroshi
    Daga, Haruko
    Takeda, Koji
    Hirashima, Tomonori
    Atagi, Shinji
    MEDICAL ONCOLOGY, 2016, 33 (01) : 1 - 7
  • [48] Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer
    Ban, Heejung
    Kim, Kyu-Sik
    Oh, In-Jae
    Yoon, Seong-Hoon
    Lee, Boram
    Yu, Jinyeong
    Kim, Sunmin
    Lee, Ho-Sung
    Shin, Hong-Joon
    Park, Cheol-Kyu
    Kwon, Yong-Soo
    Kim, Yu-Il
    Lim, Sung-Chul
    Kim, Young-Chul
    THORACIC CANCER, 2014, 5 (06) : 525 - 529
  • [49] A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
    Motohiro Tamiya
    Akihiro Tamiya
    Hiroyasu Kaneda
    Kazuhiko Nakagawa
    Kiyotaka Yoh
    Koichi Goto
    Hiroaki Okamoto
    Tsuneo Shimokawa
    Tetsuya Abe
    Hiroshi Tanaka
    Haruko Daga
    Koji Takeda
    Tomonori Hirashima
    Shinji Atagi
    Medical Oncology, 2016, 33
  • [50] Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Cui, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S3 - S3
12345